Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.
P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026
7 days ago
Trial completion date • Trial primary completion date • Metastases
The androgen receptor AR antagonists, such as enzalutamide and apalutamide, are efficient therapeutics for the treatment of prostate cancer (PCa). It potently inhibits cell growth with IC50 values of 4.87 ± 0.52 and 2.07 ± 0.34 μM in the LNCaP and 22RV1 cell lines, respectively, and exhibited effective tumor growth inhibition (TGI = 50.9 %) in the 22RV1 xenograft study. These data suggest that 20i has the potential for development as an AR/AR-V7 inhibitor with degradation ability to treat advanced prostate cancer.
16 days ago
Journal • Metastases
|
AR (Androgen receptor)
|
AR amplification • AR expression • AR splice variant 7
This real-world study on patients with mHSPC treated with apalutamide plus androgen deprivation therapy revealed robust oncological outcomes, aligning with the emerging evidence. The study's hallmark finding highlights the significance of rapid and deep PSA response as a predictor of improved oncological and survival outcomes.
This prospective phase II trial represents a critical step towards addressing the therapeutic gap in mCRPC patients harboring HRR pathway mutations, particularly in demographic regions with limited access to PARP inhibitors. Outcomes from this study will inform clinical practice and guide future phase III randomized trials, ultimately improving patient outcomes globally.
"A lower % of pts discontinued initial ARI tx, progressed to metastasis, or had AEs on daro vs enza/apa. When adjusting for observed BL factors, pts on daro had considerably lower risk of DISC and PROG vs enza/apa. This study confirms daro’s strong efficacy and favorable tolerability profile in a RW setting."
P2, N=7, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Jan 2026 --> Jan 2030 | Trial primary completion date: Jan 2024 --> Jan 2028
2 months ago
Trial completion date • Trial primary completion date • Metastases
P2, N=26, Active, not recruiting, University of California, San Francisco | Recruiting --> Active, not recruiting | N=60 --> 26 | Trial completion date: Dec 2024 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Jun 2025
2 months ago
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Metastases
P2, N=28, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
3 months ago
Trial completion date • Trial primary completion date • Metastases
The panel reached a consensus on 18 statements based on recent evidence and expert insights. These consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa.
We show that SBFI-103 is well tolerated and can strongly eliminate RCaP tumor cells in vivo. This provides a pre-clinical platform to fight incurable PC and suggests an important role for FABP5 in PTEN-deficient PC.
4 months ago
Journal
|
PTEN (Phosphatase and tensin homolog) • FABP5 (Fatty Acid Binding Protein 5)